ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer

医学 前列腺切除术 前列腺癌 泌尿科 临床终点 安慰剂 前列腺特异性抗原 前列腺 新辅助治疗 活检 随机对照试验 内科学 肿瘤科 癌症 病理 乳腺癌 替代医学
作者
Gaëtan Devos,Lorenzo Tosco,Marcella Baldewijns,Thomas Gevaert,Karolien Goffin,Valentin Petit,Cindy Mai,Annouschka Laenen,Yannic Raskin,Carl Van Haute,Lieven Goeman,Gert De Meerleer,Charlien Berghen,Wout Devlies,Frank Claessens,Hendrik Van Poppel,Wouter Everaerts,Steven Joniau
出处
期刊:European Urology [Elsevier BV]
卷期号:83 (6): 508-518 被引量:48
标识
DOI:10.1016/j.eururo.2022.09.009
摘要

High-risk prostate cancer (PCa) patients have a high risk of biochemical recurrence and metastatic progression following radical prostatectomy (RP). To determine the efficacy of neoadjuvant degarelix plus apalutamide before RP compared with degarelix with a matching placebo. ARNEO was a randomized, placebo-controlled, phase II neoadjuvant trial before RP performed between March 2019 and April 2021. Eligible patients had high-risk PCa and were amenable to RP. Patients were randomly assigned at a 1:1 ratio to degarelix (240–80–80 mg) + apalutamide (240 mg/d) versus degarelix + matching placebo for 3 mo followed by RP. Prior to and following neoadjuvant treatment, pelvic 18F-PSMA-1007 positron emission tomography (PET)/magnetic resonance imaging (MRI) was performed. The primary endpoint was the difference in proportions of patients with minimal residual disease (MRD; = residual cancer burden (RCB) ≤0.25 cm3 at final pathology). Secondary endpoints included differences in prostate-specific antigen responses, pathological staging, and change in TNM stage on prostate-specific membrane antigen (PSMA) PET/MRI following hormonal treatment. Biomarkers (immunohistochemical staining on prostate biopsy [PTEN, ERG, Ki67, P53, GR, and PSMA] and PSMA PET/MRI-derived characteristics) associated with pathological response (MRD and RCB) were explored. Patients were randomized to neoadjuvant degarelix + apalutamide (n = 45) or degarelix + matching placebo (n = 44) for 12 wk and underwent RP. Patients in the degarelix + apalutamide arm achieved a significantly higher rate of MRD than those in the control arm (38% vs 9.1%; relative risk [95% confidence interval] = 4.2 [1.5–11], p = 0.002). Patients with PTEN loss in baseline prostate biopsy attained significantly less MRD (11% vs 43%, p = 0.002) and had a higher RCB at final pathology (1.6 vs 0.40 cm3, p < 0.0001) than patients without PTEN loss. Following neoadjuvant hormonal therapy, PSMA PET–estimated tumor volumes (1.2 vs 2.5 ml, p = 0.01) and maximum standardized uptake value (SUVmax; 4.3 vs 5.7, p = 0.007) were lower in patients with MRD than in patients without MRD. PSMA PET–estimated volume and PSMA PET SUVmax following neoadjuvant treatment correlated significantly with RCB at final pathology (both p < 0.001). In high-risk PCa patients, neoadjuvant degarelix plus apalutamide prior to RP results in a significantly improved pathological response (MRD and RCB) compared with degarelix alone. Our trial results provide a solid hypothesis-generating basis for neoadjuvant phase 3 trials, which are powered to detect differences in long-term oncological outcome following neoadjuvant androgen receptor signaling inhibitor therapy. In this study, we looked at the difference in pathological responses in high-risk prostate cancer patients treated with degarelix plus apalutamide or degarelix plus matching placebo prior to radical prostatectomy. We demonstrated that patients treated with degarelix plus apalutamide achieved a significantly better tumor response than patients treated with degarelix plus matching placebo. Long-term follow-up is required to determine whether improved pathological outcome translates into better oncological outcomes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
清秀的仙人掌完成签到,获得积分10
1秒前
RayLam完成签到,获得积分10
1秒前
2秒前
以韓完成签到 ,获得积分10
2秒前
imica完成签到 ,获得积分10
3秒前
Diamond完成签到 ,获得积分10
3秒前
可耐的问柳完成签到 ,获得积分10
4秒前
HH关注了科研通微信公众号
6秒前
兔子完成签到,获得积分10
6秒前
6秒前
xxx完成签到 ,获得积分10
8秒前
ash发布了新的文献求助10
9秒前
科研通AI5应助哭泣笑柳采纳,获得10
9秒前
倾听阳光完成签到 ,获得积分10
10秒前
iPhone7跑GWAS完成签到,获得积分10
10秒前
chinbaor完成签到,获得积分10
12秒前
怡然猎豹完成签到,获得积分10
13秒前
songvv发布了新的文献求助10
13秒前
ash完成签到,获得积分10
13秒前
17秒前
shezhinicheng完成签到,获得积分10
17秒前
桃花不用开了完成签到 ,获得积分10
18秒前
futong发布了新的文献求助10
20秒前
张瑞雪完成签到 ,获得积分10
23秒前
666完成签到,获得积分10
24秒前
大模型应助大橙子采纳,获得10
24秒前
maclogos发布了新的文献求助10
25秒前
李燕完成签到,获得积分10
25秒前
hahaha完成签到,获得积分10
26秒前
长长的名字完成签到 ,获得积分10
27秒前
离子电池完成签到,获得积分10
27秒前
futong完成签到,获得积分10
28秒前
量子星尘发布了新的文献求助10
30秒前
CooL完成签到 ,获得积分10
31秒前
科学家发布了新的文献求助10
31秒前
zhang26xian完成签到,获得积分10
34秒前
天真酒窝完成签到,获得积分10
36秒前
CodeCraft应助RC_Wang采纳,获得10
37秒前
流沙无言完成签到 ,获得积分10
37秒前
40秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022